Literature DB >> 19251096

Helical tomotherapy planning for left-sided breast cancer patients with positive lymph nodes: comparison to conventional multiport breast technique.

S Murty Goddu1, Summer Chaudhari, Maria Mamalui-Hunter, Olga L Pechenaya, David Pratt, Sasa Mutic, Imran Zoberi, Sam Jeswani, Simon N Powell, Daniel A Low.   

Abstract

PURPOSE: To evaluate the feasibility of using helical tomotherapy for locally advanced left-sided breast cancer. METHODS AND MATERIALS: Treatment plans were generated for 10 left-sided breast cancer patients with positive lymph nodes comparing a multiport breast (three-dimensional) technique with the tomotherapy treatment planning system. The planning target volumes, including the chest wall/breast, supraclavicular, axillary, and internal mammary lymph nodes, were contoured. The treatment plans were generated on the tomotherapy treatment planning system to deliver 50.4 Gy to the planning target volume. To spare the contralateral tissues, directional blocking was applied to the right breast and right lung. The optimization goals were to protect the lungs, heart, and right breast.
RESULTS: The tomotherapy plans increased the minimal dose to the planning target volume (minimal dose received by 99% of target volume = 46.2 +/- 1.3 Gy vs. 27.9 +/- 17.1 Gy) while improving the dose homogeneity (dose difference between the minimal dose received by 5% and 95% of the planning target volume = 7.5 +/- 1.8 Gy vs. 37.5 +/- 26.9 Gy). The mean percentage of the left lung volume receiving >or=20 Gy in the tomotherapy plans decreased from 32.6% +/- 4.1% to 17.6% +/- 3.5%, while restricting the right-lung mean dose to <5 Gy. However, the mean percentage of volume receiving >or=5 Gy for the total lung increased from 25.2% +/- 4.2% for the three-dimensional technique to 46.9% +/- 8.4% for the tomotherapy plan. The mean volume receiving >or=35 Gy for the heart decreased from 5.6% +/- 4.8% to 2.2% +/- 1.5% in the tomotherapy plans. However, the mean heart dose for tomotherapy delivery increased from 7.5 +/- 3.4 Gy to 12.2 +/- 1.8 Gy.
CONCLUSION: The tomotherapy plans provided better dose conformity and homogeneity than did the three-dimensional plans for treatment of left-sided breast tumors with regional lymph node involvement, while allowing greater sparing of the heart and left lung from doses associated with increased complications.

Entities:  

Mesh:

Year:  2009        PMID: 19251096     DOI: 10.1016/j.ijrobp.2008.11.004

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  38 in total

1.  Simultaneous irradiation of the breast and regional lymph nodes in prone position using helical tomotherapy.

Authors:  K Kainz; J White; G-P Chen; J Hermand; M England; X A Li
Journal:  Br J Radiol       Date:  2012-03-28       Impact factor: 3.039

2.  Long-Term Pulmonary Outcomes of a Feasibility Study of Inverse-Planned, Multibeam Intensity Modulated Radiation Therapy in Node-Positive Breast Cancer Patients Receiving Regional Nodal Irradiation.

Authors:  Alice Y Ho; Ase Ballangrud; Guang Li; Gaorav P Gupta; Beryl McCormick; Richard Gewanter; Daphna Gelblum; Melissa Zinovoy; Boris Mueller; Borys Mychalczak; Pinaki Dutta; Karen Borofsky; Preeti Parhar; Marsha Reyngold; Lior Z Braunstein; Mohit Chawla; Kate Krause; Natasha Freeman; Chun Ting Siu; Zachary Cost; Brittany B Arnold; Zhigang Zhang; Simon N Powell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-30       Impact factor: 7.038

3.  Helical tomotherapy in patients with breast cancer and complex treatment volumes.

Authors:  Ricardo Cendales; Luis Schiappacasse; Franco Schnitman; Graciela García; Hugo Marsiglia
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

4.  Safety and benefit of using a virtual bolus during treatment planning for breast cancer treated with arc therapy.

Authors:  Marguerite Tyran; Agnes Tallet; Michel Resbeut; Marjorie Ferre; Veronique Favrel; Pierre Fau; Laurence Moureau-Zabotto; Julien Darreon; Laurence Gonzague; Ahcene Benkemouche; Leonel Varela-Cagetti; Naji Salem; Bertrand Farnault; Marie-Aimee Acquaviva; Hugues Mailleux
Journal:  J Appl Clin Med Phys       Date:  2018-06-30       Impact factor: 2.102

5.  First clinical report of helical tomotherapy with simultaneous integrated boost for synchronous bilateral breast cancer.

Authors:  Tabassum Wadasadawala; Shanu Jain; Siji Paul; Reena Phurailatpam; Kishore Joshi; Palak Popat; Sandip Tandon; Aruna Alahari; Rajiv Sarin
Journal:  Br J Radiol       Date:  2017-07-14       Impact factor: 3.039

6.  Breast cancer and funnel chest. Comparing helical tomotherapy and three-dimensional conformal radiotherapy with regard to the shape of pectus excavatum.

Authors:  M Uhl; F Sterzing; G Habl; K Schubert; H Holger; J Debus; K Herfarth
Journal:  Strahlenther Onkol       Date:  2012-01-06       Impact factor: 3.621

7.  Helical tomotherapy and volumetric modulated arc therapy: New therapeutic arms in the breast cancer radiotherapy.

Authors:  Olivier Lauche; Youlia M Kirova; Pascal Fenoglietto; Emilie Costa; Claire Lemanski; Celine Bourgier; Olivier Riou; David Tiberi; Francois Campana; Alain Fourquet; David Azria
Journal:  World J Radiol       Date:  2016-08-28

8.  Acute Toxicity From Breast Cancer Radiation Using Helical Tomotherapy With a Simultaneous Integrated Boost.

Authors:  Andrzej P Wojcieszynski; Anna K Olson; Yi Rong; Randall J Kimple; Poonam Yadav
Journal:  Technol Cancer Res Treat       Date:  2015-03-16

9.  Comparing four radiotherapy techniques for treating the chest wall plus levels III-IV draining nodes after breast reconstruction.

Authors:  Valentina Lancellotta; Martina Iacco; Elisabetta Perrucci; Lorenzo Falcinelli; Claudio Zucchetti; Berardino de Bari; Simonetta Saldi; Cynthia Aristei
Journal:  Br J Radiol       Date:  2018-03-19       Impact factor: 3.039

10.  Node-positive left-sided breast cancer: does VMAT improve treatment plan quality with respect to IMRT?

Authors:  M Pasler; D Georg; S Bartelt; J Lutterbach
Journal:  Strahlenther Onkol       Date:  2013-03-24       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.